USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Bridging the gap between histopathology and molecular pathology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Apollo continues to invest in genomics technology and research for better patient care
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Subscribe To Our Newsletter & Stay Updated